Jasper Therapeutics (NASDAQ:JSPR) Research Coverage Started at BTIG Research

BTIG Research assumed coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a report issued on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $90.00 price target on the stock.

Several other research firms have also issued reports on JSPR. Stifel Nicolaus began coverage on Jasper Therapeutics in a research report on Thursday, June 27th. They set a buy rating and a $86.00 target price for the company. Royal Bank of Canada began coverage on Jasper Therapeutics in a research report on Thursday, March 28th. They set an outperform rating and a $70.00 target price for the company. Evercore ISI began coverage on Jasper Therapeutics in a report on Wednesday, April 3rd. They set an outperform rating and a $65.00 price objective on the stock. Cantor Fitzgerald reiterated an overweight rating on shares of Jasper Therapeutics in a report on Tuesday, June 18th. Finally, TD Cowen began coverage on Jasper Therapeutics in a report on Monday, March 18th. They set an outperform rating on the stock. Eleven investment analysts have rated the stock with a buy rating, According to MarketBeat, Jasper Therapeutics presently has an average rating of Buy and an average price target of $69.56.

Jasper Therapeutics Stock Down 6.8 %

Shares of JSPR stock opened at $19.87 on Monday. Jasper Therapeutics has a 12 month low of $4.00 and a 12 month high of $31.01. The firm has a market cap of $299.24 million, a PE ratio of -3.53 and a beta of 2.21. The stock has a 50 day moving average of $23.04 and a 200-day moving average of $20.37.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($1.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.23. As a group, equities analysts predict that Jasper Therapeutics will post -4.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Jasper Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Ieq Capital LLC bought a new position in Jasper Therapeutics in the fourth quarter worth approximately $43,000. Monaco Asset Management SAM bought a new position in shares of Jasper Therapeutics in the fourth quarter valued at approximately $197,000. Virtu Financial LLC bought a new position in shares of Jasper Therapeutics in the first quarter valued at approximately $306,000. Fernwood Investment Management LLC lifted its holdings in Jasper Therapeutics by 8.8% during the fourth quarter. Fernwood Investment Management LLC now owns 494,706 shares of the company’s stock worth $390,000 after acquiring an additional 40,000 shares during the period. Finally, Concurrent Investment Advisors LLC bought a new stake in Jasper Therapeutics during the first quarter worth $599,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.